Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 ( GLOBE NEWSWIRE ) -- Sutro Biopharma, Inc. ( Sutro or the Company ) ( NASDAQ: STRO ) , a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ( ADCs ) , today announced that REFRαME-P1, the ...
| Ticker |
Sentiment |
Impact |
|
PCVX
|
Neutral
|
3 %
|
|
DSSMY
|
Somewhat Bullish
|
3 %
|
|
STRO
|
Neutral
|
15 %
|
